prof. dr. D.J. (Dirk-Jan) Reijngoud

Education

1972   MSc Biochemistry (cum laude) University of Amsterdam, Amsterdam, The Netherlands

1978   PhD, on the thesis entitled: ‘The pH inside lysosomes’ at the University of Amsterdam, Amsterdam, The Netherlands

1978-1981 Postdoctoral fellow at the Woman’s Medical College of Pennsylvania, Philadelphia, PA, USA, under the supervision of M.C. Phillips

Profession

1985-2012 Head of the laboratory of metabolic diseases at the University Medical Center Groningen, Groningen, The Netherlands

1995   Clinical Chemist, specialty Inborn Errors of Metabolism

2010   Professor holding the chair of ‘Inborn Variability of Metabolism’

 Grants

2013-2018    Fonds ESZ. Systems Medicine, towards diagnostics at maximum speed

2011-2015    SBC Energy Metabolism and Aging (NWO). Top-Down Analysis of metabolic stress in mice

2011-2015    SBC Energy Metabolism and Aging (NWO). Modeling of mouse metabolism

2011-2014    Metakids. Development of new therapeutic stategies in patients with glycogen storage diseases using organ-specific knock-out mouse models.

2010-2014    Netherlands Centre of System Biology. The impact of gut-derived short-chain fatty acids on hepatic fatty acid and glucose metabolism in mice.

2008-2012    RvvZ fonds. Which adaptations take place in patients with a defect in mitochondrial fatty acid oxidation.

2008-2011    MD-PhD trajectsubsidie Endocrine and metabolic abnormalities in patients with glycogen storage disease type III.

2004-2008    Diabetes Fonds Nederland. Molecular basis of fish-oil prevention of type 2 diabetes: shifting the balance between PPARα- and LXRα-controlled pathways of glucose and fat metabolism in the liver

2003-2004    Diabetes Fonds Nederland Innovatie initiatief. Critical role of glucose-6-phosphatase in development of diet-induced type II diabetes?

2002-2003    De Cock Stichting. How do the transcription factors PPARα and HNF-4α differ in their regulation of hepatic glucose metabolism?”

2001-2004    ZON-Mw. Feasibility of neonatal population screening of medium-chain acyl-CoA dehydrogenase deficiency by tandem mass spectrometry.

 Thesis

2021 Zhang W. Applying lipidomics strategies to study lipid metabolic diseases.

2019 Martines, A-C. Exploring the mechanism underlying the phenotype of MCAD deficiency with Systems Medicine: from computational model to mice to men

2017 Hijmans, B. Metabolic adaptations in models of fatty liver disease: of mice and math

2015 De Groot M. J. Phenylketonuria: towards mechanism-based treatment.

2015 Srinivasan B. Rerouting 'Coenzyme A' biosynthesis

2014  Volker-Touw C.M.L. MCAD deficiency. To be, or not to be at risk

2014  Den Besten, G. Elucidating the mechanisms of action of short-chain fatty acids. From dietary fiber to host metabolism

2010   Van Dijk TH. Computational analaysis of carbohydrate metabolism. Stable isotope techniques in small laboratory animals.

2010   M Hoeksema M. PKU: food for thought.

2009   Oosterveer MH. Control of Metabolic Flux by Nutrient Sensors.

2009   Schreurs M Regulatory enzymes of mitochondrila β-oxidation as targets for treatment of the metabolic syndrome.

2007   Derks TGJ. MCAD deficiency. Clinical and laboratory studies.

2004   Bandsma RHJ Interactions between carbohydrate and lipid metabolism in metabolic disorders.

2004   Veeneman JM Whole body protein metabolism in chronic hemodialysis.

2002   C Wiegman Interactions between hepatic glucose and fat metabolism in animal models of insulin resistance.

2001   M Roef Nutritional Management of Patients with Complex I Deficiency: A macronutrient Approach.

1998   M de Sain In Vivo Kinetics of Cardiovascular and Renal Risk Factors in Patients with Proteinuria.

1996   FJ van Spronsen Phenylketonuria: Implications of Some Biochemical and Clinical Findings.

1993   R Baarsma Glucose Kinetics and Glucose Monitoring in Newborn Infants.

1988   S Bambang Oetomo Treatment of Pulmonary Surfactant Deficiency.

1987   GPA Smit Glycogen Storage Disease Type I and III. Aspects of Energy Metabolism and Implications for Treatment.